DermKnowledgeBASE: Erythema Nodosum

Erythema Nodosum

Semantic LIterature Summary Engine (SLISE)

( SLISE(Summary) - Drag this link to bookmarks bar for instant search)

Skin Deep - A Dermatology Blog

Loading........Please wait.

The text is the summary of recent articles on Erythema Nodosum at 75 thresold from National Library of Medicine (NLM). This information is subject to NCBI's Disclaimer and Copyright notice.

In earlier qualitative studies, C1q has been implicated in the pathogenesis of erythema nodosum Leprosum (ENL) [1]. The mRNA expression of the three C1q components, C1qA, C1qB, and C1qC in the peripheral blood and skin biopsies was determined by qPCR [2]. Circulating C1q in the peripheral blood of untreated ENL patients was significantly decreased compared to LL patient controls [3]. Untreated ENL patients had increased C1q gene expression in the peripheral blood compared to LL controls [4]. Similarly, C1qA and C1qC gene expression were substantially increased in the skin biopsies of untreated ENL patients compared to LL controls [5].

In contrast to the often-insidious onset, slow disease progression and Chronic disease course typical of sarcoidosis, Lofgren syndrome presents acutely, in younger Caucasian patients with acute onset erythema nodosum, Bilateral hilar lymphadenopathy, Fever, and migratory polyarthritis, without Granulomatous skin involvement [6]. Clinicians who treat IBD must manage EIMs affecting Multiple organs that variably correlate with intestinal disease activity [7]. The supernatants were assessed with the enzyme-linked immunosorbent assay for inflammatory and regulatory cytokines [8]. For cytokine gene expression, mRNA was isolated from whole blood and skin lesions and then reverse transcribed into cDNA [9]. The mRNA expression in blood and skin Lesion for TNF, IFN-γ, IL-1β, IL-6, and IL-17A significantly reduced in patients with ENL after treatment, while mRNA expression for IL-10 and TGF-β was significantly increased both in blood and skin Lesion after treatment [10].

Ramiro Barcelos, 2350, Santa Cecília, Porto Alegre, RS, Brazil [11]. Corticosteroid is the anti-inflammatory of choice in ENL but may cause dependence, especially for chronic patients [12]. However, this was not the case for the extraocular manifestations, since TCZ was only effective in three of them [13]. erythema nodosum leprosum (ENL), a type 2 lepra reaction, occurs in lepromatous or borderline lepromatous cases, usually in response to multidrug therapy [14]. We report two clinically unusual cases of ENL on fine-needle aspiration cytology [15].

Like all cases of Sarcoidosis, it is of unknown aetiology and may constitute a diagnostic difficulty in the ambiguous phenotype [16]. It is being progressively recognised as a multisystemic disease, with Multiple extraintestinal manifestations [17]. Two of them concern linear iga Bullous dermatosis and erythema nodosum, which have been described in the literature as having potential associations with CD, though only a few cases were reported [18]. As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases [19]. In the present review, preclinical data about the effects of thalidomide and its analogues on the Immune system are integrated, including the effects of cytokines on transdifferentiation, the anti-inflammatory effect, immune cell function regulation and angiogenesis [20].

Although Erythema Nodosum Leprosum (ENL) is an Inflammatory complication of leprosy, the role of B- cell subsets has never been studied in this patient group [21]. The kinetics of B-cells in patients with ENL before, during and after Prednisolone treatment of ENL was compared with LL patient controls as well as within ENL group [22]. We investigated the effects of moderate 20 mmHg to 30 mmHg compression stockings as an alternative treatment method in two Female patients with Recurrent erythema nodosum [23]. At the follow-up visit, the EN lesions were no longer Tender to the touch, and postinflammatory hyperpigmentation changes had started [24]. The purpose of this study is to determine the clinical and demographic characteristics of 11 IGM and EN patients and to evaluate the efficacy of methylprednisolone treatment [25].

He developed numerous erythema nodosum leprosum-like mucocutanous lesions accompanied by Fever, Generalized lymphadenopathy, and weight loss [26]. In the present article, we provide a systematic literature review on skin manifestations linked to each of these four autoimmune liver diseases, excluding skin manifestations of systemic diseases [27]. erythema nodosum Leprosum (ENL) is an immune-mediated Inflammatory complication, which causes significant morbidity in affected leprosy patients [28]. Preferred treatment modalities are systemic corticosteroids and thalidomide [29]. Complete withdrawal of Oral prednisolone after gradual tapering was possible by 12 months of Azathioprine therapy [30].

Although erythema nodosum leprosum (ENL) is an Inflammatory complication of leprosy, the role of memory T cell subsets has never been studied in this patient group [31]. The mucocutaneous lesions are varied: urticaria, angioedema, atopic Dermatitis, erythema nodosum, wells syndrome, among others [32]. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects [33]. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature [34]. However, autoimmune toxicities are common and often significant adverse events with these agents [35].

Although the findings were clinically concerning for disease Recurrence, histopathologic examination of biopsies from the lesions revealed a Subcutaneous mixed septal and Lobular erythema nodosum-like panniculitis [36].

References: 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ,

Press Refresh to fetch fresh content with references from pubmed. This content was cached on

comments powered by Disqus


This is an experimental application for healthcare professionals. The information presented here is not intended to diagnose, treat, cure or prevent any disease. Read disclaimer. - Evidence based skincare free

About Me

I have varied research interests ranging from eHealth, Health Information Exchange, Clinical Trials and Research, Contact Dermatitis, Bioinformatics, and Cosmetic Dermatology. I have work experience in Canada as an eHealth analyst, and in Dubai and India as a Specialist Dermatologist.


Bell Raj Eapen
Hamilton, ON